Osteoporosis Treatment in Lumbar Fusion: A Scoping Review.
Salman Samer G SG, Phadke Rohan A RA, Franco Adam S AS, Tummala Sri S et al.
Perioperative pharmacologic bone-health optimization is increasingly recommended before lumbar fusion, but the supporting evidence may not apply to short-segment degenerative fusion. This scoping review mapped how well treatment recommendations are supported in that population. Of 1,842 records screened, 145 underwent full-text review and 54 met inclusion criteria. Most high-level evidence pooled degenerative disease with adult spinal deformity and osteoporotic vertebral fracture without construct-specific analysis. In short-segment degenerative fusion, small teriparatide studies reported lower screw loosening and higher or earlier union, whereas a 1,040-patient registry found no reduction in operative nonunion with preoperative bisphosphonates. High-quality short-segment data for romosozumab and abaloparatide were absent, and timing and duration were inconsistent. Recommendations are supported by biologic rationale but limited by population mismatch. Teriparatide has the strongest degenerative-specific signal; evidence for bisphosphonates and newer agents is insufficient. Future trials should isolate 1- to 2-level degenerative fusion and prioritize cage subsidence, screw loosening, fusion, and reoperation.